Viroptic

Company
King Pharmaceuticals

Approval Status
Approved February 1998

Treatment for
inflammation of the cornea due to herpes simplex virus

Areas
Immune System , Eye Health / Ophthalmology , Pediatrics

Viroptic Oththalmic Solution (trifluridine) 1% has been approved for use in children (ages 6+) as a treatment for inflammation of the cornea caused by the herpes simplex virus. The antiviral agent was previously approved for use in adults.

Viroptic Drug Information

The Viroptic drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top